Management of Angioedema and Mucositis as Oral Manifestations of Juvenile Systemic Lupus Erythematosus
DOI:
https://doi.org/10.18196/di.v14i1.26204Keywords:
angioedema, mucositis, juvenile Systemic Lupus ErythematosusAbstract
Angioedema and mucositis are rare in juvenile systemic lupus erythematosus (jSLE) and increase morbidity and mortality in an individual under 18 years. This case report aims to describe the management of an 11-year-old female patient with a history of jSLE, presenting with swelling of her lip, difficulty in speaking, oral pain since a month ago, and self-medicating, which led to the swelling becoming worse. Full blood count, immunology, and antigen laboratory examination indicated anemia normocytic normochromic, leukopenia, hypoalbuminemia, vitamin D deficiency, proteinuria, neonatal lupus erythematosus, and Sjogren’s syndrome. Methylprednisolone, mycophenolate mofetil, and hydroxychloroquine sulfate were given by the pediatrician. Medications consisted of topical application of 0.1%triamcinolone acetonide in orabase for angioedema and mucositis, benzydamine hydrochloride oral rinse before meals, chlorhexidine gluconate and 0.025% hyaluronic acid mouthwash after meals and before bed. Oral complaints and lesions have improved within 10 days. High caution, specific examinations to determine the type of angioedema, collaboration with pediatric rheumatologists, and systemic treatment of SLE must be supported by topical therapy to treat AE and mucositis, which are oral manifestations of SLE.
References
Prenzel F, Abraham S, Hirche C, et al. Epidemiology and treatment of children with hereditary angioedema in Germany: A retrospective database study. Clin Transl Allergy. 2023;13(11):1-9. https://pubmed.ncbi.nlm.nih.gov/38006382/
Sokay A, Byrne A, Killeen OG, Rea D, Leahy TR. Acquired Angioedema in a Child with Systemic Lupus Erythematosus. Ir Med J. 2021;114(9):0-4. https://imj.ie/wp-content/uploads/2021/10/Acquired-Angioedema-in-a-Child-with-Systemic-Lupus-Erythematosus.pdf
Hahn J, Greve J, Bas M, Kojda G. Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs. Drugs Drug Candidates. 2023;2(3):708-727. https://www.mdpi.com/2813-2998/2/3/36
Luo Y, Fan X, Jiang C, et al. Systemic lupus erythematosus and angioedema: A cross-sectional study from the National Inpatient Sample. Arch Rheumatol. 2019;34(3):301-307. https://pubmed.ncbi.nlm.nih.gov/31598596/
Harry O, Yasin S, Brunner H. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr. 2018;196:22-30.e2. https://pubmed.ncbi.nlm.nih.gov/29703361/
Charras A, Smith EMD, Hedrich CM, et al. Systemic Lupus Erythematosus in Children and Young People. Curr Rheumatol Rep. 2021;23(20):1-15. https://doi.org/10.1016/j.clim.2019.108274
Du F, Qian W, Zhang X, Zhang L, Shang J. Prevalence of oral mucosal lesions in patients with systemic Lupus Erythematosus: a systematic review and meta-analysis. BMC Oral Health. 2023;23(1):1-10. https://pubmed.ncbi.nlm.nih.gov/38129844/
Verdelli A, Corrà A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Pediatr Drugs. 2021;23:331-347. https://pubmed.ncbi.nlm.nih.gov/36213629/
Rasheed TP, Jabeen M, Iqbal SA, et al. Angioedema as a Presenting Feature in a Patient With SLE : A Case Report. Cureus. 2024;16(10):1-7. https://pubmed.ncbi.nlm.nih.gov/39564035/
Munthe EKM, Sufiawati I. Oral lesions as a clinical sign of systemic lupus erythematosus. Dent J. 2018;51(3):147-152. https://e-journal.unair.ac.id/MKG/article/view/8419
Kumar N, Surendran D, Bammigatti C. Angioedema as the presenting feature of systemic lupus erythematosus. BMJ Case Rep. 2018;2018:2-4. https://pubmed.ncbi.nlm.nih.gov/29593002/
Sami FL, Sami HL, Tahir H, Guan J. Angioedema as a Rare Presentation of Systemic Lupus Erythematosus. Cureus. 2022;14(11):4-9. https://pubmed.ncbi.nlm.nih.gov/36569666/
Levy D, Craig T, Keith PK, Krishnarajah G, Beckerman R, Prusty S. Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: A systematic literature review. Allergy, Asthma Clin Immunol. 2020;16(41):1-8. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-020-00437-x
García-Ríos P, Pecci-Lloret MP, Oñate-Sánchez RE. Oral Manifestations of Systemic Lupus Erythematosus: A Systematic Review. Int J Environ Res Public Heal. 2022;19(19):1-12. https://pubmed.ncbi.nlm.nih.gov/36231212/
Schildt E, Sessions KL, De Ranieri D. Juvenile Systemic Lupus Erythematosus Presenting with Esophagitis and Severe Oral Mucositis. Case Rep Rheumatol. 2021;2021(Table 1):1-4. https://pubmed.ncbi.nlm.nih.gov/34123454/
Wira Rajasa AS, Hidayat W. Oral Lesion Management in Juvenile SLE with Hepatosplenomegaly. Int Med Case Rep J. 2024;17:695-702. https://pubmed.ncbi.nlm.nih.gov/39076507/
Ali MR, Zaidan TF. The association of cluster of differentiation 34 gene (CD34) polymorphism with oral ulceration in systemic lupus erythematosus Iraqi patients. Int J Pharm Res. 2020;12(1):716-722. http://www.ijpronline.com/ViewArticleDetail.aspx?ID=12588
Fourie J, Boy SC. Oral mucosal ulceration a clinician’s guide to diagnosis and treatment. South African Dent J. 2016;71(10):500-508. https://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0011-85162016001000017
Pan L, Liu J, Liu C, Guo L, Punaro M, Yang S. Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol. 2023;14(August):1-11. https://pubmed.ncbi.nlm.nih.gov/37638017/
Petri M. Drug monitoring in systemic lupus erythematosus. Curr Opin Pharmacol. 2022;64:1-19. https://pubmed.ncbi.nlm.nih.gov/35490454/
Sagcal-gironella ACP, Merritt A, Mizuno T, et al. Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis–A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). J Clin Trials. 2024;14(4):1-10. https://pubmed.ncbi.nlm.nih.gov/39035447/
Smith EMD, Egbivwie N, Jorgensen AL, et al. Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clin Immunol. 2022;239(April):109028. https://pubmed.ncbi.nlm.nih.gov/35513304/
Rodsaward P, Prueksrisakul T, Deekajorndech T, Edwards SW, Beresford MW, Chiewchengchol D. Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature. Am J Clin Dermatol. 2017;18(6):755-762. https://pubmed.ncbi.nlm.nih.gov/28477309/
Suebsarakam P, Mairiang D. Accuracy and adequacy of photoprotection in pediatric systemic lupus erythematosus patients, and the effect of education on photoprotection: a prospective study. Pediatr Rheumatol. 2023;21(1):1-10. https://pubmed.ncbi.nlm.nih.gov/37848991/
Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Pediatr Drugs. 2021;23(4):331-347. https://pubmed.ncbi.nlm.nih.gov/34244988/
Teixeira Santos FPS, Ferreira GA, de Paula JJ, de Souza KCP, Cançado Silva SL, Correa H. Cognitive dysfunction in patients with childhood-onset systemic lupus erythematosus may impact treatment. Adv Rheumatol. 2023;63(1):1-8. https://pubmed.ncbi.nlm.nih.gov/37095585/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Manuel Dwiyanto Hardjo lugito
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License
Insisiva Dental Journal : Majalah Kedokteran Gigi Insisiva (IDJ) is licensed under an Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially. This license is acceptable for Free Cultural Works.
The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Copyright
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under an Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
